Q-omics provides the consensus-scored ZBTB32 profile across patient tissues and cancer cell-line models. ZBTB32 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ZBTB32 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, ZBTB32 RNA expression shows 16,066 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, and UVM as cancer lineages where ZBTB32 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZBTB32 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZBTB32 survival associations across molecular data types. ZBTB32 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZBTB32 RNA expression–survival associations across cancer types. High ZBTB32 expression shows unfavorable associations in ACC, but favorable associations in HNSC, SKCM, UCS, CESC and BLCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ZBTB32 RNA expression.
This table summarizes ZBTB32 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for ZBTB32. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZBTB32 shows higher tumor expression in HNSC, KIRC, LIHC, STAD, BRCA and CHOL. The HNSC box plot shows higher ZBTB32 RNA expression in tumor versus normal tissue (log2 FC = +0.671, t-test p < 0.001).
This table shows molecular features associated with ZBTB32 in patient tissues and cancer cell lines. In patient samples, ZBTB32 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZBTB32 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and SOFT_TISSUE.
